UCB Agrees To Pay $34M Over Epilepsy Drug Labeling

Law360, New York (June 9, 2011, 2:58 PM EDT) -- The U.S. subsidiary of Belgian pharmaceuticals manufacturer UCB SA pled guilty Thursday to the off-label promotion of its epilepsy drug Keppra, and agreed to pay more than $34 million to resolve criminal and civil liability.

Smyrna, Ga.-based UCB Inc. pled guilty to a misdemeanor in connection with the company’s misbranding of Keppra in violation of the Federal Food, Drug and Cosmetic Act.

The government said the guilty plea and a related civil settlement marked a victory as prosecutors team up with the U.S. Department of Health...
To view the full article, register now.